Chengdu Kanghua Biological Products Past Earnings Performance
Past criteria checks 2/6
Chengdu Kanghua Biological Products has been growing earnings at an average annual rate of 18.2%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 12% per year. Chengdu Kanghua Biological Products's return on equity is 15.4%, and it has net margins of 34.4%.
Key information
18.2%
Earnings growth rate
14.0%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 12.0% |
| Return on equity | 15.4% |
| Net Margin | 34.4% |
| Next Earnings Update | 17 Aug 2024 |
Revenue & Expenses Breakdown
How Chengdu Kanghua Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,611 | 553 | 605 | 230 |
| 31 Dec 23 | 1,577 | 509 | 611 | 253 |
| 30 Sep 23 | 1,382 | 484 | 553 | 238 |
| 30 Jun 23 | 1,421 | 531 | 558 | 218 |
| 31 Mar 23 | 1,458 | 568 | 562 | 208 |
| 01 Jan 23 | 1,447 | 598 | 545 | 180 |
| 30 Sep 22 | 1,567 | 729 | 555 | 161 |
| 30 Jun 22 | 1,400 | 893 | 515 | 113 |
| 31 Mar 22 | 1,322 | 864 | 507 | 83 |
| 01 Jan 22 | 1,292 | 829 | 507 | 79 |
| 30 Sep 21 | 993 | 648 | 397 | 67 |
| 30 Jun 21 | 1,136 | 478 | 457 | 72 |
| 31 Mar 21 | 1,119 | 444 | 468 | 72 |
| 31 Dec 20 | 1,039 | 408 | 445 | 58 |
| 30 Sep 20 | 1,085 | 442 | 455 | 51 |
| 30 Jun 20 | 739 | 285 | 324 | 37 |
| 31 Mar 20 | 581 | 216 | 266 | 22 |
| 31 Dec 19 | 555 | 187 | 275 | 23 |
| 30 Sep 19 | 425 | 101 | 243 | 21 |
| 31 Dec 18 | 559 | 154 | 312 | 19 |
| 31 Dec 17 | 262 | 74 | 132 | 4 |
| 31 Dec 16 | 93 | 7 | 53 | 6 |
| 31 Dec 15 | 71 | 12 | 27 | 5 |
Quality Earnings: 300841 has high quality earnings.
Growing Profit Margin: 300841's current net profit margins (34.4%) are lower than last year (39%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300841's earnings have grown by 18.2% per year over the past 5 years.
Accelerating Growth: 300841's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300841 had negative earnings growth (-2.6%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).
Return on Equity
High ROE: 300841's Return on Equity (15.4%) is considered low.